Aska Pharmaceutical Holdings Co., Ltd. · TSE:4886
Aska Pharmaceutical — Q2 FY2021 Earnings Presentation
46 slides from Aska Pharmaceutical's earnings presentation, Nov 16, 2021
Slide 1: Consolidated Financial Results for the Second Quarter FY2021
November 16, 2021 Consolidated Financial Results for the Second Quarter of the Year Ending in March 31, 2022 (FY2021) Presentation for Investors Stock code : 4886 (TSE) ASKA Pharmaceutical Holdings Co., Ltd.
Slide 2: Forward Looking Statement
Forward Looking Statement The forward-looking statements contained in this presentation are based the Company’s assumptions and beliefs in the light of information currently available to it and involves known and unknown risks and uncertainties. Accordingly, there is a possibility that actual re
Slide 3: Financial Results Summary for 2Q FY2021
Financial Results Summary for 2Q FY2021 Atsushi Maruo, Member of the Board of Directors ASKA Pharmaceutical Holdings Co., Ltd.
Slide 4: Consolidated Statements of Income
Consolidated Statements of Income *The figures announced as ASKA Pharmaceutical Co., Ltd. *FY2020 Apr - Sep FY2021 Apr - Sep Actual +/- Growth +/- (Millions of yen) Actual Actual Net sales 27,403 28,477 1,074 3.9% Cost of sales 14,563 15,051 488 3.4% Gross profit 12,840 13,426 586 4.6% Selling, gene
Slide 5: Net Sales by Business (Consolidated)
Net Sales by Business (Consolidated) *The figures announced as ASKA Pharmaceutical Co., Ltd. *FY2020 FY2021 Apr - Sep Apr - Sep Breakdown Actual +/- Growth +/- (Millions of yen) Actual Actual Pharmaceutical drugs 25,128 25,619 90.0% 491 2.0% Animal health drugs 2,232 2,791 9.8% 559 25.0% Others 42 6
Slide 6: Sales of Main Products
Sales of Main Products FY2020 FY2021 Reference Products FY2021 Area Apr - Sep Apr – Sep Pre-revision (generic name) Actual Actual YOY (％) Forecast YOY (％) Forecast CANDESARTAN *1, *2 (candesartan) 6,117 6,259 102.3% 11,651 94.5% 10,605 THYRADIN Internal Medicine (levothyroxine) 3,579 3,790 105.9% 7,
Slide 7: Analysis of Operating Profit (YOY)
Analysis of Operating Profit (YOY) (Millions of yen) 397 261 2,657 337 327 1,946 586 FY2020 Apr - Sep Increase in Increase in Decrease in Decrease in Increase in FY2021 Apr - Sep Actual gross profit sales promotion depreciation R&D expenses other expenses Actual expenses and travel/ transportation e
Slide 8: Consolidated Balance Sheet
Consolidated Balance Sheet End of FY2020 (Millions of yen) End of FY2021 (Millions of yen) Current liabilities Assets Current liabilities 16,737 16,124 Cash and deposits -397 Current assets （-613） Notes and accounts receivable 1,698 39,932 Non-current Current assets Property, plant and equipment -
Slide 9: FY2022 Forecast (Consolidated)
FY2022 Forecast (Consolidated) FY2021 FY2020 YOY YOY Forecast Actual Actual +/- % +/- (Millions of yen) (update) Net sales 55,181 54,500 (681) (1.2%) Operating profit 3,609 3,500 (109) (3.0%) Ordinary profit 3,092 3,600 508 16.4% Profit attributable to owners of parent 2,713 (2,600) (5,313) - Major
Slide 10: Reference information
Reference information Capital Expenditures Depreciation and Amortization R&D expenses (Including intangible assets, consolidated basis) (Millions of yen) (Millions of yen) (Millions of yen) 4,913 4,709 Forecast 3,977 3,669 3,305 Forecast 2,941 2,240 Forecast 1,092 2Q Actual 766 2Q Actual 1,941 1,346
Slide 11: Reference information: Shareholder Returns
Reference information Shareholder Returns Following the policy of ASKA Pharmaceutical Co., Ltd., ASKA Pharmaceutical Holdings' basic policy is to continue paying a stable and continuous dividends in order to provide appropriate return on profit for shareholders. 100th anniversary Commemorative divid
Slide 12: Overview of the 2Q FY2021 Interim Annual Report
Overview of the 2Q FY2021 Interim Annual Report Takashi Yamaguchi, President, Representative Director ASKA Pharmaceutical Holdings Co., Ltd.
Slide 13: ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co., Ltd. Transition to a Holding Company structure Medium-term management plan 2025 objectives Overview of each subsidiary 13
Slide 14: ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co., Ltd. Equity-method subsidiaries ASKA Ha Tay Pharmaceutical Pharmaceutical Holdings Joint Stock Company (Shareholding ratio: 24.9%) あすか あすか製薬 JAPAN GLASS ASKA ASKA ASKA アニマルヘルス メディカル INDUSTRY CO., LTD. Animal Health Pharmaceutical Pharma Medical (Shareholding ratio:
Slide 15: Transition to a holding company structure
Transition to a holding company structure "Become a Total Healthcare Company with a Strong Foundation as a Specialty Pharma Company” The Medium-Term Management Plan 2025 Numerical Targets Net sales: 70 billion yen, Operating profit rate: 8%, ROE: 8% Based on this foundation, The Medium-Term Manageme
Slide 16: Overview of each subsidiary (Net sales for 2Q FY2021)
Overview of each subsidiary (Net sales for 2Q FY2021) ASKA Pharmaceutical Holdings Co., Ltd. Net sales Net sales Net sales ¥2,791 million ¥28,477 million ¥66 million 9.8% 0.2% Pharmaceutical Drugs （ASKA Pharmaceutical） Net sales ¥25,619 million 90.0% 16
Slide 17: ASKA Pharmaceutical Co., Ltd.
ASKA Pharmaceutical Co., Ltd. Major Initiatives Strengthening the Specialty Therapeutic Areas Engaging in alliance activities and development pipeline Global Expansion 17
Slide 18: Prediction of the Obs/Gyn market and ASKA's Numerical Targets
ASKA Pharmaceutical Co., Ltd. Prediction of the Obs/Gyn market and ASKA’s Numerical Targets The obstetrics and gynecology (Obs/Gyn) market is projected to grow by an average of about 3% annually. (Forecast from 2019 to 2027) ASKA (forecast) Over ¥20 billion Growth factors ¥82.6* billion ASKA (foreca
Slide 19: Obs/Gyn Products by Life Stage
ASKA Pharmaceutical Co., Ltd. Obs/Gyn Products by Life Stage Early Puberty Reproductive age Menopause Old age childhood Oral contraception LF111 ANGE NORLEVO Menopause HOLIN Iron deficiency anemia Riona (Co-Pro) Menstrual disorder PLANOVAR *1 RELUMINA is in application process for an additional indi
Slide 20: Growth Driver – The Potential of RELUMINA (relugolix)
ASKA Pharmaceutical Co., Ltd. Growth Driver – The Potential of RELUMINA (relugolix)- Uterine fibroids treatment status Market share of uterine fibroid therapeutic agents (Enlarged estimation from electronic receptacle data) RELUMINA LEUPRORELIN 1.88mg Estimated number of patients 100% Patients diagn
Slide 21: Growth Driver – The Potential of RELUMINA (relugolix)
ASKA Pharmaceutical Co., Ltd. Growth Driver – The Potential of RELUMINA (relugolix)- RELUMINA Endometriosis treatment status Sales trends Net Sales forecast FY2025 (Enlarged estimation from electronic receptacle data) over ¥10 billion Patients diagnosed with uterine fibroids forecast (790,000) Finan
Slide 22: Sustained Growth of LEP Formulations (Jemina and FREWELL)
ASKA Pharmaceutical Co., Ltd. Sustained Growth of LEP* Formulations（Jemina and FREWELL） *Low-dose Estrogen/Progestin combination LEP market continues to expand Source: Encise Inc. (unauthorized reproduction prohibited) Expansion factors thousand tablets 90,000 Increasing number of women are contro
Slide 23: Responding to Unmet Medical Needs by RIFXIMA
ASKA Pharmaceutical Co., Ltd. Responding to Unmet Medical Needs by RIFXIMA Clinical Practice Guidelines for Cirrhosis 2020 Initiatives of RIFXIMA Strength of recommendation: Evidence level: Awareness-raising activities for asymptomatic Strongly recommended A Applicable partial summary: hepatic enc
Slide 24: Initiatives of the Thyroid Area
ASKA Pharmaceutical Co., Ltd. Initiatives of the Thyroid Area Responsibilities as a Leading Company Initiatives of the Thyroid Area Continue to raise awareness of diseases. Considering a new project to Securing of a stable supply. coincide with the 100th anniversary Respond to medical needs.
Slide 25: Drug Discovery Promotion (Alliance Activities)
ASKA Pharmaceutical Co., Ltd. Drug Discovery Promotion (Alliance Activities) Option agreement regarding the treatment for cervical dysplasia. Co-development and option agreement in the field of gynecology. Adopted for CiCLE business by AMED Joint research agreement on drug discovery research. Aim to
Slide 26: Development Pipeline
ASKA Pharmaceutical Co., Ltd. Development Pipeline R&D Status (as of November 2021) Development code (generic name) Ph I Ph II Ph III Application Approval Indication TAK-385 (relugolix) Filed Endometriosis LF111 (drospirenone) Ph II Completed Contraception (option agreement) Under development at Ren
Slide 27: Relugolix Combination Tablet (TAK-385)
ASKA Pharmaceutical Co., Ltd. New Development Relugolix Combination Tablet (TAK-385) Licensing agreement with Takeda Pharmaceutical Company Limited. September 27, 2021 Summary Entered into a license agreement for exclusive development and commercialization for uterine fibroids in Japan. Combinat
Slide 28: Adhesion Barrier (TRM-270C)
ASKA Pharmaceutical Co., Ltd. New Development Adhesion Barrier* (TRM-270C) Signed business collaboration agreement with Toray Industries, Inc. October 5, 2021 Summary Jointly develop the Product to obtain a marketing approval. Commercialization exclusively for Japan. Use during medical procedu
Slide 29: Business Development in Asia
ASKA Pharmaceutical Co., Ltd. Business Development in Asia Equity-method affiliate Vietnam Ha Tay Pharmaceutical Joint Stock Company (Hataphar) Two members of ASKA were appointed as directors of Hatapher, and participate in management. Support the construction for a new factory compatible with P
Slide 30: ASKA Animal Health Co., Ltd.
ASKA Animal Health Co., Ltd. 30
Slide 31: Overview of ASKA Animal Health Co., Ltd.
ASKA Animal Health Co., Ltd. Overview of ASKA Animal Health Co., Ltd. Business Companion animal-related Manufacture and sale of animal health products, feed, feed additives and raw materials, etc. Others Fisheries 3% 5% Vision medicine 9% Become the one and only company that supports the health of c
Slide 32: Major Initiatives for 2Q FY2021
ASKA Animal Health Co., Ltd. Major Initiatives for 2Q FY2021 Launched three new mixed feed products in April 2021 Mixed feed for Dermanyssus gallinae control Nucleic acid-containing yeast feed WAKUMOHATE NUCLEOFORCE LIVESTOCK NUCLEOFORCE AQUA Yeast activity feed for ruminant VISTACERE ”PRIDDELTA*”
Slide 33: ASKA Pharma Medical Co., Ltd.
ASKA Pharma Medical Co., Ltd. 33
Slide 34: Overview of ASKA Pharma Medical Co., Ltd.
ASKA Pharma Medical Co., Ltd. Overview of ASKA Pharma Medical Co., Ltd. Business Endogenous hormone microanalysis (Steroid hormones, thyroid hormones, etc.) Clinical testing and biological testing Owned patent Priority Targets Analysis of steroid hormones Expansion of business through hair-growth
Slide 35: Initiatives of Major Themes for 2Q FY2021
ASKA Pharma Medical Co., Ltd. Initiatives of Major Themes for 2Q FY2021 Collaboration with ASKA Hair-growth diagnostics Pharmaceutical's healthcare business Launched hair-growth hormone analysis kit. Create synergies Collaboration with ASKA Thyroid disease business Pharmaceutical's sales headquarter
Slide 36: Promote ESG Management
Promote ESG Management DC ASKA Pharmaceutical Holdings Co., Ltd. ,,
Slide 37: Promote ESG Management and Identify Materiality
ASKA Pharmaceutical Holdings Co., Ltd. Promote ESG Management and Identify Materiality We have established an ESG committee and identified 17 materialities from the perspective of relevance to our business and social contribution. most important Environment Reduction of environmental burden.. Env
Slide 38: Promote ESG Management and Contribute to SDGs
ASKA Pharmaceutical Holdings Co., Ltd. Promote ESG Management and Contribute to SDGs Become a Total Healthcare Company Social with a Strong Foundation Identifying and addressing as a Specialty Pharma Company responsibility materiality Social issues Stakeholder request Established ESG committee Prior
Slide 39: Corporate Message: For a Healthy Tomorrow and Future
ASKA Pharmaceutical Holdings Group Corporate Message For a Healthy Tomorrow and Future.
Slide 40: Appendix
Appendix DC ASKA Pharmaceutical Holdings Co., Ltd. 40
Slide 41: Transition to a New Drug-Based Business
Transition to a New Drug-Based Business Sales Proportion of Brand-name Drugs FY2021 2Q Previous medium-term management plan period (ASKA PLAN 2020) FY2020 49.8% 50.2％ FY2018 46.8％ 53.2% FY2016 39.5％ 60.5% Aim to increase the ratio of brand-name 35.8％ ■ Brand-name drugs drugs. ■ Generic drugs 64.2% 4
Slide 42: Development of AKP-009
Development of AKP-009 Outline of clinical trial Ph II clinical trial (randomized, double-blind, parallel-controlled trial with placebo control). Target: Patients with benign prostatic hyperplasia Number of cases: Approximately 100. Number of drug administrations: Once daily. Evaluation parameters i
Slide 43: Initiative for a Healthy Management
Initiative for a Healthy Management Acquired “Gold Prize” certificate for Health Management. (ASKA Pharmaceutical Co., Ltd.) Received from Health and Productivity Management Declaration Council in Tokyo (Excellent health management) (No. 97) 協金第97号 Following the silver prize certificate, we addresse
Slide 44: CSR Activities in FY2021
CSR Activities in FY2021 ASKA Pharmaceutical contribute to Women’s Health Issues through a number of projects: (Women's Health Week Event) *1 *2 (Marunouchi Career Academy) (Comfortable Menstruation Project) *1：https://special.nikkeibp.co.jp/atclh/DRS/20/seirikaiteki/ *2：https://whasympo.com/ 44
Slide 45: Social Contribution Activity
Social Contribution Activity "Health Lab for Women Mint⁺", which provides information on women's body and health, has started new activities for the younger generation as it has launched the website “Mint⁺ teens" for young people. Mint+ teens HP：https://www.aska-pharma.co.jp/mint/teens/ 45
Slide 46: Inquiries
Inquiries Corporate Planning Department Tel ： +81-3-5484-8366 e-mail： kouhou@aska-pharma.co.jp 46
ASKA Pharmaceutical Holdings — Q2 FY2021 Earnings Presentation on 6ix